Literature DB >> 7717462

Establishment and characterization of two divergent cell lines derived from a human chromophobe renal cell carcinoma.

C D Gerharz1, R Moll, S Störkel, U Ramp, B Hildebrandt, G Molsberger, P Koldovsky, H E Gabbert.   

Abstract

The chromophobe renal cell carcinoma is a distinct type of renal cancer presumably derived from the intercalated cell of the collecting duct system and exhibiting a better prognosis than other types of renal cell carcinoma. Chromophobe carcinomas can be separated from other types of renal cell carcinoma by their characteristic cytomorphology, ultrastructural appearance, cytoskeletal architecture, and cytogenetic aberrations. As no permanent cell line of the chromophobe tumor type has previously been described, we are the first to report on the successful establishment and characterization of two divergent permanent cell lines, ie, chrompho-A and chrompho-B, derived from the same chromophobe renal cell carcinoma. With immunocytochemistry, two-dimensional gel electrophoresis, and Western blot, chrompho-A and chrompho-B exclusively exhibited cytokeratins (Nos. 7, 8, 18, and 19) but not vimentin. Ultrastructural studies revealed numerous cytoplasmic microvesicles as well as coated vesicles that are known to be characteristic features of the intercalated cell. Chrompho-B cells exhibited a shorter mean population doubling time (tD = 43 hours) than chrompho-A cells (tD = 51 hours). Both cell lines failed to produce tumors in nude mice with the subrenal capsule assay. Cytogenetic analyses revealed hyperdiploid chromosome numbers in both cell lines with telomeric associations as well as numeric aberrations known from chromophobe renal cell carcinomas in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7717462      PMCID: PMC1869263     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Separation of cytokeratin polypeptides by gel electrophoretic and chromatographic techniques and their identification by immunoblotting.

Authors:  T Achtstaetter; M Hatzfeld; R A Quinlan; D C Parmelee; W W Franke
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

2.  Apical membrane endocytosis via coated pits is stimulated by removal of antidiuretic hormone from isolated, perfused rabbit cortical collecting tubule.

Authors:  K Strange; M C Willingham; J S Handler; H W Harris
Journal:  J Membr Biol       Date:  1988-07       Impact factor: 1.843

3.  The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct.

Authors:  S Störkel; P V Steart; D Drenckhahn; W Thoenes
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

4.  Renal tumor in a 62-year-old male.

Authors:  R A Erlandson; V E Reuter
Journal:  Ultrastruct Pathol       Date:  1988 Sep-Oct       Impact factor: 1.094

5.  Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro.

Authors:  C D Gerharz; R Moll; S Störkel; U Ramp; W Thoenes; H E Gabbert
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

6.  Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.

Authors:  W Thoenes; S Störkel; H J Rumpelt
Journal:  Pathol Res Pract       Date:  1986-05       Impact factor: 3.250

Review 7.  Molecular differential pathology of renal cell tumours.

Authors:  G Kovacs
Journal:  Histopathology       Date:  1993-01       Impact factor: 5.087

8.  Chromophobe cell renal carcinoma and its variants--a report on 32 cases.

Authors:  W Thoenes; S Störkel; H J Rumpelt; R Moll; H P Baum; S Werner
Journal:  J Pathol       Date:  1988-08       Impact factor: 7.996

9.  Expression of intermediate filament proteins in subtypes of renal cell carcinomas and in renal oncocytomas. Distinction of two classes of renal cell tumors.

Authors:  S Pitz; R Moll; S Störkel; W Thoenes
Journal:  Lab Invest       Date:  1987-06       Impact factor: 5.662

10.  Structure of the novel membrane-coating material in proton-secreting epithelial cells and identification as an H+ATPase.

Authors:  D Brown; S Gluck; J Hartwig
Journal:  J Cell Biol       Date:  1987-10       Impact factor: 10.539

View more
  5 in total

Review 1.  Current perspectives in cancer proteomics.

Authors:  Miriam V Dwek; Sarah L Rawlings
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

2.  Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Authors:  Youfeng Yang; Cathy D Vocke; Christopher J Ricketts; Darmood Wei; Hesed M Padilla-Nash; Martin Lang; Carole Sourbier; J Keith Killian; Shawna L Boyle; Robert Worrell; Paul S Meltzer; Thomas Ried; Maria J Merino; Adam R Metwalli; W Marston Linehan
Journal:  Genes Chromosomes Cancer       Date:  2017-07-24       Impact factor: 5.006

3.  Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterisation of four permanent cell lines.

Authors:  C D Gerharz; B Hildebrandt; R Moll; U Ramp; M Sarbia; S Störkel; P Koldovsky; H E Gabbert
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

4.  Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.

Authors:  U Ramp; M Dejosez; C Mahotka; B Czarnotta; T Kalinski; M Wenzel; I Lorenz; M Müller; P Krammer; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

5.  Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma.

Authors:  Carmen Priolo; Damir Khabibullin; Ed Reznik; Harilaos Filippakis; Barbara Ogórek; Taylor R Kavanagh; Julie Nijmeh; Zachary T Herbert; John M Asara; David J Kwiatkowski; Chin-Lee Wu; Elizabeth P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-11       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.